Thomas Cestare, MD
Interventional Pain Medicine · Brandywine, MDNPI 1013303320
Payments from drug & device makers
What this record shows
Medtronic accounts for 61.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,144 and has fallen 75.6% since, to $279 in 2022. That places this record below the midpoint for interventional pain medicine clinicians in MD, where the typical reported total is $3,506.
Across 17 payments — averaging $102.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Nevro Corp.$266
- Abbott$178
- Avanos Medical$113
- GRT US Holding, Inc.$101
- SPR Therapeutics, Inc$13
What the payments were for
- Travel & lodging$72141%
- Food & beverage$1,02459%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $1,074 |
| Nevro Corp. | 2 | $266 |
| Abbott | 1 | $178 |
| Avanos Medical | 3 | $113 |
| GRT US Holding, Inc. | 1 | $101 |
| SPR Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$824
- Senza Spinal Cord Stimulation System$266
- PROCLAIM$178
- Qutenza$101
How this compares
$1,745 in reported general payments places this provider in the 25th percentile of 56 interventional pain medicine providers in Maryland.
See all interventional pain medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 18 | $2,267 |
| Gabapentin | 146 | $1,943 |
| Pregabalin | 71 | $1,816 |
| Diclofenac Sodium | 20 | $587 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $357 |
| Baclofen | 11 | $262 |
| Duloxetine Hcl | 11 | $221 |
| Meloxicam | 21 | $133 |
| Cyclobenzaprine Hcl | 22 | $110 |
| Tramadol Hcl | 31 | $102 |
| Tizanidine Hcl | 18 | $42 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Brandywine
- Mark ColemanPikesville$1.3M
- Marc LoevRockville$318K
- Anish PatelFrederick$311K
- Aneesh SinglaSalisbury$167K
- Charles SimmonsAnnapolis$62K
- Ali El-MohandesHagerstown$57K
- Michael WongBel Air$31K
- Anna IrwinBethesda$30K
- Dontese NicholsonBaltimore$27K
- Rajesh JariNottingham$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.